290 related articles for article (PubMed ID: 20498498)
1. [The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease].
Orlik B; Handzlik G; Olszanecka-Glinianowicz M
Postepy Hig Med Dosw (Online); 2010 May; 64():212-9. PubMed ID: 20498498
[TBL] [Abstract][Full Text] [Related]
2. Adipokines in nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1062-79. PubMed ID: 26725002
[TBL] [Abstract][Full Text] [Related]
3. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
[TBL] [Abstract][Full Text] [Related]
4. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease.
Tönjes A; Blüher M; Stumvoll M
Curr Pharm Des; 2010 Jun; 16(17):1921-8. PubMed ID: 20370670
[TBL] [Abstract][Full Text] [Related]
5. Adipokines and cytokines in non-alcoholic fatty liver disease.
Jarrar MH; Baranova A; Collantes R; Ranard B; Stepanova M; Bennett C; Fang Y; Elariny H; Goodman Z; Chandhoke V; Younossi ZM
Aliment Pharmacol Ther; 2008 Mar; 27(5):412-21. PubMed ID: 18081738
[TBL] [Abstract][Full Text] [Related]
6. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance.
Baranova A; Gowder SJ; Schlauch K; Elariny H; Collantes R; Afendy A; Ong JP; Goodman Z; Chandhoke V; Younossi ZM
Obes Surg; 2006 Sep; 16(9):1118-25. PubMed ID: 16989692
[TBL] [Abstract][Full Text] [Related]
7. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis.
Tilg H
Curr Pharm Des; 2010 Jun; 16(17):1893-5. PubMed ID: 20370678
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
Polyzos SA; Kountouras J; Zavos C
Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
[TBL] [Abstract][Full Text] [Related]
9. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance.
Pagano C; Soardo G; Pilon C; Milocco C; Basan L; Milan G; Donnini D; Faggian D; Mussap M; Plebani M; Avellini C; Federspil G; Sechi LA; Vettor R
J Clin Endocrinol Metab; 2006 Mar; 91(3):1081-6. PubMed ID: 16394091
[TBL] [Abstract][Full Text] [Related]
10. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease.
Ayonrinde OT; Olynyk JK; Beilin LJ; Mori TA; Pennell CE; de Klerk N; Oddy WH; Shipman P; Adams LA
Hepatology; 2011 Mar; 53(3):800-9. PubMed ID: 21374659
[TBL] [Abstract][Full Text] [Related]
11. The epidemiology, pathogenesis and histopathology of fatty liver disease.
Levene AP; Goldin RD
Histopathology; 2012 Aug; 61(2):141-52. PubMed ID: 22372457
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease and metabolic syndrome in postmenopausal women.
Rodrigues MH; Bruno AS; Nahas-Neto J; Santos ME; Nahas EA
Gynecol Endocrinol; 2014 May; 30(5):325-9. PubMed ID: 24460502
[TBL] [Abstract][Full Text] [Related]
13. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.
Boutari C; Perakakis N; Mantzoros CS
Endocrinol Metab (Seoul); 2018 Mar; 33(1):33-43. PubMed ID: 29589386
[TBL] [Abstract][Full Text] [Related]
14. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes.
Grønbaek H; Thomsen KL; Rungby J; Schmitz O; Vilstrup H
Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):705-11. PubMed ID: 19072347
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
[TBL] [Abstract][Full Text] [Related]
16. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
[TBL] [Abstract][Full Text] [Related]
17. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
18. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy.
Tsochatzis EA; Papatheodoridis GV; Archimandritis AJ
Mediators Inflamm; 2009; 2009():831670. PubMed ID: 19753129
[TBL] [Abstract][Full Text] [Related]
19. The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease.
Boutari C; Tziomalos K; Athyros VG
Hippokratia; 2016; 20(4):259-263. PubMed ID: 29416297
[TBL] [Abstract][Full Text] [Related]
20. [Adipocitokines and nonalcoholic steatohepatitis].
Lăcătuşu C; Mihai B; Cijevschi-Prelipcean C; Mihai C; Graur M
Rev Med Chir Soc Med Nat Iasi; 2008; 112(4):882-9. PubMed ID: 20209757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
